Product Description.:
Suppos , white , bullet other
PROCTOCORT? is available either as a 1% hydrocortisone cream or a 30 mg hydrocortisone acetate suppository to provide soothing relief from anal itching, burning, and inflammation. The cream is a nonstaining, water miscible preparation with a mild unique acid mantle base. The suppository provides convenient, accurate, and consistent dose administration for problems requiring a higher potency agent.
Anusol-HC? (hydrocortisone cream, 2.5%) and PROCTOCORT? (hydrocortisone cream, 1%) are both indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Anusol-HC? (hydrocortisone acetate suppository, 25 mg) and PROCTOCORT? (hydrocortisone acetate suppository, 30 mg) are both indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis, as an adjunct in the treatment of chronic Ulcerative Colitis, cryptitis, and other inflammatory conditions of the anorectum, and pruritis ani.
Anusol-HC and PROCTOCORT are contraindicated in patients with a history of hypersensitivity to any of the components. Adverse effects include various types of skin and hair follicle irritation such as burning and itching, which may necessitate discontinuing product. Any infection should be treated if response is not prompt, the corticosteroid should be discontinued until the infection clears. These products are in Pregnancy Category C therefore, topical corticosteroids should be used during the pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. Caution is advised for use in nursing mothers.
Creams: If hypothalamic-pituitary-adrenal (HPA) axis suppression occurs, withdraw the drug, and use supplemental systemic corticosteroid (if necessary), reduce frequency of application, or substitute less potent steroid. Treated skin should not be bandaged or otherwise covered unless directed by a physician. If infection develops when using occlusive dressings, discontinue dressings and institute antimicrobial therapy. For pediatric patients use in smallest area possible and avoid chronic use, as pediatric patients may be more susceptible to systemic toxicity.
